DBT helps in early detection of breast cancer compared to mammography: Study

Breast cancer screening programs using mammography have successfully reduced mortality from the disease by catching it in its earliest, most treatable stages. However, mammography has some limitations, including a reduced sensitivity for cancer detection in dense breasts. It also produces a higher than optimal recall rate, or the rate at which women are called back for additional imaging based on uncertain results.

DBT, also known as 3D mammography, addresses some of these limitations. In DBT, a series of X-ray images are acquired from a moveable arm that makes an arc around the breast. European screening trials have found significantly increased cancer detection rates with DBT, with recall rates lower than or comparable to mammography.

Pairing DBT with synthetic mammography, a technique in which 2D images are reconstructed from the DBT data, reduces radiation exposure, making the combination viable for screening programs.

Despite its promise, few results are available about subsequent outcomes after screening with DBT--a shortfall researchers from the Verona Pilot Study in Italy have been working to address.

"An organization needs two things to improve the results of a screening program," said study lead author Francesca Caumo, M.D., from the Breast Radiology Department of the Veneto Institute of Oncology in Padua, Italy. "It needs a better first level test and a way to overcome the effect of breast density to define the risk of a patient. The Verona Pilot Study wants to answer to the first point, showing the validity of DBT as a screening test, instead of traditional mammography."

In the study, Dr. Caumo and colleagues analyzed results from more than 32,000 women who were screened for breast cancer and then rescreened two years later. After a first round of imaging by DBT with synthetic mammography, approximately half of the study participants were rescreened by DBT and synthetic mammography and the other half by mammography.

A total of 32,870 women, average age 58, were rescreened, including 16,198 with DBT synthetic mammography and 16,672 with mammography.

Digital breast tomosynthesis at the first round and at rescreening detected a higher proportion of early-stage cancers than screening with digital mammography.

The cancer detection rate was 8.1 per 1,000 for rescreening with DBT and synthetic mammography compared with 4.5 per 1,000 for rescreening with mammography. There was no difference in the recall rate at rescreening with both DBT and synthetic mammography and mammography.

At rescreening, the proportion of tumors stage-II or above was 14.5% with DBT and synthetic mammography, considerably higher than the 8.5% rate with mammography.

"The lower number of stage II or above cancers with the DBT plus synthetic mammography screening test demonstrates that DBT has the capability of anticipating the detection of cancers that might become advanced in the following two years," Dr. Caumo said. "This gives a higher benefit to our patients."

For the next step in the Verona Pilot Study, the researchers plan to complete an analysis of interval cancers, or cancers that appear in the period between screenings.

Dr. Caumo is also exploring the impact of incorporating volumetric breast density measurements into the patient's risk profile through her Risk Based Breast Screening (RiBBS) project. Approximately 10,000 women will undergo the DBT plus synthetic mammography screening test. All the women whose breast density is found to be above a certain threshold value will then be asked to receive additional breast imaging with ultrasound.

"The main goal of this research is to demonstrate that a personalized model of screening is more efficient than a normal one that I like to call a 'one size fits all' program, in which every woman must do an annual mammography screening test without any risk stratification," Dr. Caumo said. "The risk category will determine the intervals of the subsequent screening event: biennial for low-risk women and annual for intermediate and high-risk women.